GALT 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• our NAVIGATE trial was our only active clinical trial, and we currently do not have plans or funding to undertake another clinical trial;

• we have from time to time faced substantial doubt about our ability to continue as a going concern;

• we have incurred significant operating losses since our inception and cannot assure you that we will generate revenue or profit;

• we may be unable to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates;

• uncertainties related to our technology and clinical trials, including expected dates of availability of clinical data;

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• we have incurred significant operating losses since our inception and cannot assure you that we will generate revenue or profit,

• we may be unable to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates,

• uncertainties related to our technology and clinical trials, including expected dates of availability of clinical data,

• we may be unable to demonstrate the efficacy and safety of our developmental product candidates in human trials,

• we may be unable to improve upon, protect and/or enforce our intellectual property,

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• As previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, we identified a material weakness in our internal control over financial reporting. Specifically, we did not implement and maintain effective controls related to the valuation of derivative liabilities as…

• In an effort to address the identified material weakness and enhance our internal controls related to our valuation of derivative liabilities process, we continue to maintain our financial reporting process we followed to prepare consolidated financial statements in accordance with GAAP for audit co…

• Notwithstanding the material weakness, our management has concluded that the consolidated financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformit…